Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

526 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy.
Geboers B, Meijer D, Counter W, Blazevski A, Thompson J, Doan P, Gondoputro W, Katelaris A, Haynes AM, Delprado W, O'Neill G, Yuen C, Vis AN, van Leeuwen PJ, Ho B, Liu V, Lee J, Donswijk ML, Oprea-Lager D, Scheltema MJ, Emmett L, Stricker PD. Geboers B, et al. Among authors: yuen c. BJU Int. 2024 Apr;133 Suppl 4:14-22. doi: 10.1111/bju.16207. Epub 2023 Nov 8. BJU Int. 2024. PMID: 37858931
Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68 Ga-PSMA PET to mpMRI.
Scheltema MJ, Chang JI, Stricker PD, van Leeuwen PJ, Nguyen QA, Ho B, Delprado W, Lee J, Thompson JE, Cusick T, Spriensma AS, Siriwardana AR, Yuen C, Kooner R, Hruby G, O'Neill G, Emmett L. Scheltema MJ, et al. Among authors: yuen c. BJU Int. 2019 Nov;124 Suppl 1:42-49. doi: 10.1111/bju.14794. Epub 2019 Jul 9. BJU Int. 2019. PMID: 31287613
High-dose rate brachytherapy compared with open radical prostatectomy for the treatment of high-risk prostate cancer: 10 year biochemical freedom from relapse.
Savdie R, Symons J, Spernat D, Yuen C, Pe Benito RA, Haynes AM, Matthews J, Rasiah KK, Jagavkar RS, Yu C, Fogarty G, Kattan MW, Brenner P, Sutherland RL, Stricker PD. Savdie R, et al. Among authors: yuen c. BJU Int. 2012 Dec;110 Suppl 4:71-6. doi: 10.1111/j.1464-410X.2012.11480.x. BJU Int. 2012. PMID: 23194129
68Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery.
Nandurkar R, van Leeuwen P, Stricker P, Woo H, Kooner R, Yuen C, O'Neill G, Ende D, Cusick T, Ho B, Hickey A, Emmett L. Nandurkar R, et al. Among authors: yuen c. Br J Radiol. 2019 Mar;92(1095):20180667. doi: 10.1259/bjr.20180667. Epub 2019 Jan 23. Br J Radiol. 2019. PMID: 30563350 Free PMC article. Clinical Trial.
The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.
Amin A, Scheltema MJ, Shnier R, Blazevski A, Moses D, Cusick T, Siriwardena A, Yuen B, van Leeuwen PJ, Haynes AM, Matthews J, Brenner P, O'Neill G, Yuen C, Delprado W, Stricker P, Thompson J. Amin A, et al. Among authors: yuen c, yuen b. J Urol. 2020 May;203(5):910-917. doi: 10.1097/JU.0000000000000693. Epub 2019 Dec 11. J Urol. 2020. PMID: 31825297 Clinical Trial.
Final Analysis of the Magnetic Resonance Imaging in Active Surveillance Trial.
Doan P, Scheltema MJ, Amin A, Shnier R, Geboers B, Gondoputro W, Moses D, van Leeuwen PJ, Haynes AM, Matthews J, Brenner P, O'Neill G, Yuen C, Delprado W, Stricker P, Thompson J. Doan P, et al. Among authors: yuen c. J Urol. 2022 Nov;208(5):1028-1036. doi: 10.1097/JU.0000000000002885. Epub 2022 Aug 10. J Urol. 2022. PMID: 35947521 Clinical Trial.
526 results